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LIST OF ABBREVIATIONS 
 
GMS – Glasgow Microenvironment Score 
DFS – Disease-free survival 
RFS – Relapse-free survival 
OS – Overall survival 
CSS – Cancer-specific survival 
HR – Hazard ratio 
CI – Confidence interval 
FOLFOX – chemotherapy regimen of Folinic acid, 5-FU and Oxaliplatin 
CAPOX – chemotherapy regimen of Capecitabine and Oxaliplatin 
CRC – Colorectal cancer 
TNM – Tumour, Node, Metastasis staging system 
TSP – Tumour stromal percentage 
KM – Klintrup-Mäkinen grade 
H&E – haematoxylin and eosin staining 




Background:  The Glasgow Microenvironment Score (GMS) combines peritumoural 
inflammation and tumour stroma percentage to assess interactions between tumour and 
microenvironment. This was previously demonstrated to associate with colorectal cancer 
(CRC) prognosis, it now requires validation and assessment of interactions with adjuvant 
therapy. 
Patients and Methods:  Two cohorts were utilised; 862 TNM I-III CRC validation cohort, 
and 2912 TNM II-III CRC adjuvant chemotherapy cohort (TransSCOT). Primary endpoints 
were disease-free survival (DFS) and relapse-free survival (RFS). Exploratory endpoint was 
adjuvant chemotherapy interaction. 
Results:  GMS independently associated with DFS (p=0.001) and RFS (p<0.001).  GMS 
significantly stratified RFS for both low-risk (GMS0 v GMS2: HR 3.24 95% CI 1.85-5.68, 
p<0.001) and high-risk disease (GMS0 v GMS2: HR 2.18 95% CI 1.39-3.41, p=0.001). In 
TransSCOT, chemotherapy type (pinteraction=0.013), but not duration (p=0.64) was dependent 
on GMS. Furthermore, GMS 0 significantly associated with improved DFS in patients 
receiving FOLFOX compared with CAPOX (HR 2.23 95% CI 1.19-4.16, p=0.012). 
Conclusions: This study validates the GMS as a prognostic tool for patients with stage I-III 
colorectal cancer, independent of TNM, with the ability to stratify both low- and high-risk 
disease. Furthermore, GMS 0 could be employed to identify a subset of patients that benefit 




Colorectal cancer (CRC) poses a significant burden on healthcare worldwide, with 1.8 
million CRC-related deaths in 20181. TNM staging remains the primary tool for guiding 
prognosis and management following CRC resection2, 3. However, there are wide variations 
in prognosis for individuals within the same TNM-stage4. Further, high-risk features have 
been identified for stage II disease selecting patients for consideration of adjuvant therapy5, 6. 
However, Dienstmann et al.4, when analysing the relative impact of TNM, 
clinicopathological features and molecular markers on survival outcomes, reported that the 
additional features to the TNM only modestly increased prognostic accuracy. 
Clearly, further prognostic markers are required and the interaction between host and 
tumour is integral to this process. Two independent prognostic scoring systems assessing the 
tumour microenvironment have been developed, namely tumour stromal percentage (TSP) 
and an assessment of peritumoural inflammation, both of which remain optional in the 
current edition of the Royal College of Pathologists colorectal cancer reporting dataset3. As 
the local inflammatory response is fundamental in orchestrating host anti-tumour immunity7, 
an increase in infiltrating immune cell density is recognised as a stage-independent 
favourable prognostic characteristic8, 9 and a recent study in colon cancer highlighted tumour 
immunity as pivotal to accurate assessment of recurrence risk in conjunction with TNM10. 
Similarly, higher TSP is a validated, poor prognostic marker independent of TNM in CRC11 
and has more recently been associated with the mesenchymal consensus molecular subtype12. 
Assessment of the inflammatory cell infiltrate and mesenchymal phenotype retain 
independent and complementary prognostic value in patients with operable CRC, and several 
groups have proposed their combined assessment as an adjunct to staging13-15. The Glasgow 
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Microenvironment Score (GMS) combines assessment of peritumoural inflammation, using 
the Klintrup-Mäkinen grade (KM), with assessment of TSP, both performed on routinely 
available haematoxylin and eosin (H&E)-stained sections11, 16, 17. Its clinical utility has been 
reported in a discovery cohort, stratifying five-year cancer-specific survival of 307 patients 
with stage I-III CRC into three distinct groups13.  
The GMS now requires validation and could provide a platform on which to develop 
personalized treatment approaches for CRC, which is also important for adjuvant 
chemotherapy, where biomarkers are lacking. For example, the SCOT trial recently 
demonstrated patients receiving CAPOX (capecitabine and oxaliplatin) have similar survival 
with 3- versus 6-months duration, whereas patients receiving FOLFOX (bolus and infused 
fluorouracil with oxaliplatin) may benefit from 6-months duration18, 19. Therefore, it is 
important to identify patients who may benefit from a longer and more intensive 
chemotherapy regimen.  Recently we investigated the utility of a histopathology-based 
classification of the Consensus Molecular Subtypes called Phenotypic Subtypes, 
incorporating KM grade, TSP and the proliferation marker Ki6720. This stratified 
chemotherapy response in a cohort of 1343 patients from the adjuvant chemotherapy SCOT 
trial (TransSCOT), with the predictive power of this subtyping predominantly related to 
assessment of KM grade and TSP.  Therefore, it was deemed more appropriate and pragmatic 
in the current study to use GMS to assess the expanded cohort in preference to Phenotypic 
Subtypes, since the GMS can be performed on H&E slides that are routinely used in 
histopathological staining without the need for immunohistochemistry.    
Therefore, the primary aim of the present study was to assess the validity of the GMS 
as a prognostic score in two independent cohorts: an expanded validation cohort of stage I-III 
CRC patients and the full TransSCOT cohort. The exploratory aim was to assess associations 






The validation cohort included 862 TNM I-III CRC, combining individuals from the 
discovery Glasgow Royal Infirmary cohort (n=231) with additional patients identified 
retrospectively from other Glasgow hospitals (Western Infirmary, Gartnavel General and 
Stobhill Hospitals) who had undergone surgery with curative intent from 2000-2007 (n=631). 
Patients undergoing palliative or endoscopic resections and those with involved surgical 
margins (R1 resections) were excluded.  In the TransSCOT cohort there were 2912 patients 
with available tissue from the SCOT adjuvant chemotherapy trial (ISRCTN no. 59757862) 
who had undergone potentially curative resection for high-risk TNM II or TNM III CRC 
from 2008-2013 within the UK. All patients were followed up for at least 3 years. 30-day 
surgical mortalities were excluded from both cohorts. 
Study Endpoints 
The primary endpoint was disease-free survival (DFS; measured from date of 
surgery/randomization to date of recurrence or all-cause mortality) for both the validation and 
TransSCOT cohorts. In addition, relapse-free survival (RFS; measured from date of surgery 
to date of recurrence or CRC-related mortality), cancer-specific survival (CSS; measured 
from date of surgery until CRC-related mortality) and overall survival (OS; measured from 
date of surgery until all-cause mortality) were calculated for the validation cohort. 
Furthermore, the interaction between GMS, adjuvant chemotherapy type and duration and 
DFS was examined in the TransSCOT cohort.  Survival data for the validation cohort was 
complete up until 9th February 2017 which acted as censor date, and until end of study period 




Clinical characteristics were recorded from patient case notes, and pathological 
characteristics, including TNM, were collected from pathology reports. Venous invasion was 
assessed using H&E-stained sections (both intra- and extra-mural invasion considered 
present). Those from Glasgow Royal also had elastica staining performed for venous invasion. 
The fifth edition of TNM staging system was used, consistent with the Royal College of 
Pathologists reporting guidelines during the time period studied. Clinical risk was assessed 
using the Petersen index to indicate low- and high-risk TNM stage II disease5: a score of 1 
was assigned to venous invasion or peritoneal involvement; a score of 2 was assigned to 
tumour perforation. Individuals with a Petersen index of ≥2 were considered high risk. 
Emergency surgery was defined as unplanned surgery within 5-days of index hospital 
admission. Modified Glasgow Prognostic score (mGPS) was calculated as previously 
described21 using serum C-reactive protein (CRP) and albumin levels measured in the 30 
days preceding elective surgery, and on day of admission for emergency surgery. Data 
regarding adjuvant chemotherapy was not available for this cohort.  
TransSCOT cohort 
 The TransSCOT cohort comprised 2912 patients from the SCOT study of adjuvant 
chemotherapy, with study criteria and clinicopathological characteristics previously 
described18.  Briefly, the cohort comprised of patients with stage III and high-risk stage II 
(one or more of T4 disease, tumour obstruction with or without perforation of the primary 
tumour preoperatively, fewer than ten lymph nodes harvested, poorly differentiated histology, 
perineural invasion, or extramural venous or lymphatic vascular invasion), treated with 
FOLFOX or CAPOX adjuvant chemotherapy randomized to 3- or 6-months’ duration.  
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Tumours were staged using 7th edition of TNM. Date and site of recurrence and cause of 
death were crosschecked using electronic case records for both cohorts. 
Assessment of the tumour microenvironment 
Whole H&E-stained sections of the deepest point of invasion were used for scoring 
the tumour microenvironment. Slides were scanned onto Slidepath Digital Image Hub, 
version 4.0.1 (Leica Biosystems, UK) using a Hamamatsu NanoZoomer at x20 magnification 
(Welwyn Garden City, UK). GMS combines KM and TSP assessment, as described 
previously11. In brief, KM was scored semi-quantitatively at the invasive margin of the 
tumour as weak (none or only mild increase in inflammatory infiltrate) or strong (prominent 
inflammatory band or cup-like infiltrate). TSP was scored by assigning a percentage of the 
proportion of tumour-associated stroma present, including areas of mucin, at x20 
magnification. This was then dichotomised to low (≤50% stroma) or high (>50% stroma). 
KM and TSP were then combined: strong KM, regardless of TSP, scored GMS 0; weak KM 
with low TSP scored GMS 1; and weak KM with high TSP scored GMS 2. TSP and KM 
were already available for a subset of 1343 patients in the TransSCOT cohort, as these were 
utilized for assessing the Phenotypic Subtypes. For all microenvironment scoring, 10% of 
cases were co-scored with an intra-class correlation co-efficient of >0.7.   
Immunohistochemistry for generic T-cell (CD3) and cytotoxic (CD8) T-cell densities 
within the invasive margin, tumour stroma and cancer cell nests had previously been 
performed and reported for a subset of the validation cohort9. In addition, a composite 
CD3/CD8 score comprising respective densities in the tumour centre and invasive margin 




Mutational analysis was performed on a subset of patients from the validation cohort 
(n=251). DNA was extracted from FFPE sections by NHS Tayside diagnostics and stored at -
80oC. DNA concentration was determined using Qubit assays (Thermo Fisher Scientific, MA, 
USA) and samples with ≥150ng DNA were included in the study. DNA was diluted to 4ng/µl 
and transferred to barcoded library tubes. Sequencing was performed by the Glasgow 
Precision Oncology Laboratory (GPOL) using the GPOL 151 CORE Cancer gene panel and 
run on a HiSeq4000 (Illumina, CA, USA). Data for KRAS and BRAF were converted to 
mutation annotation format and analysed using BiocManager maftools package in RStudio (R 
Studio, Inc, MA, USA). 
Statistical analysis 
All data were subsequently analysed using SPSS version 25.0 (IBM SPSS). Kaplan-
Meier and log-rank analysis compared survival adjusted for T-stage, N-stage and treatment 
duration, where appropriate. Hazard ratios (HR) and confidence intervals (CI) were 
calculated from univariate Cox regression survival analysis. Multivariable survival analysis 
using a backward conditional elimination model and a statistical significance threshold of p-
value<0.1 was performed to identify independent prognostic biomarkers. Text results are 
reported as HR, 95% CI for GMS 0 vs GMS 2, but p-value given is for log-rank analysis of 
overall trend. Pearson chi-squared test was used to test associations between categorical 
variables and GMS. A Cox proportional hazard (PH) interaction model was performed to 
assess interactions between GMS and treatment type/duration. The study conformed to the 





In the validation cohort, there were 862 patients with TNM I-III CRC. 
Clinicopathological characteristics are presented in Table 1. Sixty percent of patients were 
younger than 75 years at time of surgery, and 35% were node positive. Fifty-eight percent 
had low-risk disease, while 42% had high-risk disease. Of the high-risk group, 61 were high-
risk TNM II, whereas 302 were TNM III. Three hundred (35%) patients were GMS 0, 424 
(49%) patients GMS 1 and 138 (16%) patients GMS 2. Median follow-up for all patients was 
7.96 years (range: 2.3-11.1). There were 554 deaths and 271 patients developed recurrence.  
Associations between GMS and DFS were assessed (Table 1). GMS stratified survival 
in the whole cohort for DFS with 5-year DFS for GMS 0, 1 and 2 of 71%, 58% and 46%, 
respectively (GMS 0 v GMS 2: HR 1.50 95% CI 1.16-1.93, p=0.002; Figure 1A).  On 
multivariate analysis for DFS, GMS remained independent (p=0.004) of age (p<0.001), T-
stage (p=0.003), N-stage (p<0.001) and mGPS (p<0.001). Subgroup analysis was performed 
according to clinical risk (low risk: TNM I-II and Petersen Index <2; high-risk: TNM II and 
Petersen index ≥2 or TNM III) and primary tumour site (Table 2). While GMS did not 
stratify survival in low-risk disease (Figure 1B), high-risk disease was stratified with 5-year 
DFS for GMS 0, 1 and 2 of 66%, 43% and 38%, respectively (GMS 0 v GMS 2: HR 1.72 
95% CI 1.19-2.47, p=0.003; Figure 1C). In addition, GMS was able to stratify 5-year DFS for 
colon cancer with GMS 0, 1 and 2 of 72%, 58% and 45%, respectively (GMS 0 v GMS 2: 
HR 1.57 95% CI 1.16-2.12, p=0.004; Figure S1A), but not rectal cancer (S1B). 
Next, associations between GMS and RFS were assessed (Table 1). GMS 
significantly stratified RFS for the whole cohort with 5-year RFS of 83%, 70% and 51% for 
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GMS 0, 1 and 2, respectively (GMS 0 v GMS 2: HR 3.09 95% CI 2.19-4.36, p<0.001, Figure 
1D). On multivariate analysis for RFS, GMS remained associated with survival (p<0.001) 
independent of T-stage (p=0.001), N-stage (p<0.001), venous invasion (p=0.04) and mGPS 
(p<0.001). In low-risk disease (Table 2), 5-year RFS was 88%, 84% and 63% for GMS 0, 1 
and 2, respectively, with GMS 2 associated with significantly worse RFS (GMS 0 v GMS 2: 
HR 3.24 95% CI 1.85-5.68, p<0.001, Figure 1E). In high-risk disease (Table 2), 5-year RFS 
was 72%, 51% and 43% for GMS 0, 1 and 2, respectively, and GMS 0 had significantly 
better RFS (GMS 0 v GMS 2: HR 2.18 95% CI 1.39-3.41, p=0.001, Figure 1F). On subgroup 
analysis by disease site (Table 2), GMS stratified RFS in patients with colon cancer (n=650), 
with 5-year RFS for GMS 0, 1 and 2 of 84%, 69% and 51%, respectively (GMS 0 v GMS 2: 
HR 3.15 95% CI 2.08-4.77, p<0.001, Figure S1C), and rectal cancer (n=212), with 5-year 
RFS for GMS 0, 1 and 2 of 80%, 72% and 51%, respectively (GMS 0 v GMS 2: HR 2.95 
95% CI 1.58-5.48, p=0.001 Figure S1D). 
Overall (OS) and cancer-specific survival (CSS) data were available for the validation 
cohort and these are displayed in Supplementary Tables S1-2 and Figure S2. GMS was 
independently significant on multivariate analysis for OS (p<0.01) and for CSS (p<0.001). 
On subgroup analysis for OS, the results were comparable to DFS, with GMS stratifying OS 
for the full cohort (GMS 0 v GMS 2: HR 1.50 95% CI 1.17-1.93, p=0.003), high-risk disease 
(GMS 0 v GMS 2: HR 1.67 95% CI 1.18-2.38, p=0.009), and colon cancer (GMS 0 v GMS 2: 
HR 1.49 95% CI 1.11-2.00, p=0.02), but not low-risk disease or rectal cancer. Likewise, the 
subgroup analysis for CSS was similar to that for RFS, with GMS stratifying CSS for the full 
cohort (GMS 0 v GMS 2: HR 3.55 95% CI 2.44-5.16, p<0.001), low-risk disease (GMS 0 v 
GMS 2: HR 3.94 95% CI 2.10-7.39, p<0.001), high risk disease (GMS 0 v GMS 2: HR 2.34 
95% CI 1.46-3.76, p=0.001), colon cancer (GMS 0 v GMS 2: HR 3.36 95% CI 2.14-5.27, 
p<0.001) and rectal cancer (GMS 0 v GMS 2: HR 4.07 95% CI 2.08-7.96, p<0.001). 
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The relationship between GMS and pattern of recurrence was examined 
(Supplementary Table S3). GMS 1 and 2 were associated with higher risk of recurrence 
(GMS 0 - 15%, GMS 1 – 26%, GMS 2 – 41%, p<0.001.) Although this was predominantly 
due to an increase in risk of distant recurrence, patients with GMS 2 were more likely to 
develop local recurrence compared to GMS 0 or 1.  
Furthermore, associations between GMS and CD3, CD8 and composite CD3/CD8 
score were assessed (Table S4, n=208). GMS was associated with individual T-cell densities 
in all locations and composite score, with highest density observed in GMS 0 and lowest 
density generally observed in GMS 2. Univariate survival analysis found comparable hazard 
ratios and confidence intervals for all immune cell markers. These were not combined in 
multivariate analysis as all included analysis of an inflammatory variable and would therefore 
be mutually exclusive. 
The relationship between GMS and clinicopathological characteristics was examined 
(Table 1). Increasing GMS was significantly associated with younger age (p=0.04), 
emergency presentation (p=0.002), high-risk TNM (p<0.001), higher T- and N-stage (both 
p<0.001), peritoneal involvement (p<0.001) and venous invasion (p<0.001). There were no 
significant associations between GMS and KRAS or BRAF mutations. Neither were these 





In the TransSCOT cohort, there were 2912 TNM II-III patients, all of whom received 
FOLFOX (n=846) or CAPOX (n=2066) adjuvant chemotherapy for at least 3 months. 383 
(13%) patients were GMS 0, 1866 (64%) patients GMS 1, and 663 (23%) patients GMS 2.  
Median follow up was 3.0 years (range: 0.0-7.0) with 755 DFS events. Cohort characteristics 
shown in Table 3 were similar to those in the full SCOT trial and therefore representative of 
this population18. 
In the full cohort, GMS significantly stratified survival with a 5-year DFS for GMS 0, 
1 and 2 of 69%, 63% and 53%, respectively (GMS 0 v GMS 2: HR 1.68 95% CI 1.28-2.20, 
p<0.001, Figure 2A). Patients were then stratified for disease site. In patients with colon 
cancer (n=2402), GMS stratified survival, with 5-year DFS for GMS 0, 1 and 2 of 76%, 66% 
and 56%, respectively (GMS 0 v GMS 2: HR 2.20 95% CI 1.64-2.94, p<0.001, Figure S3A). 
For patients with rectal cancer (n=510), GMS did not associate with DFS (GMS 0 v GMS 2: 
HR 1.74 95% CI 0.85-3.57, p=0.130, Figure S3B). On multivariate analysis (Table 3), T-
stage (p<0.001), N-stage (p<0.001) and GMS (p<0.001) independently associated with DFS.  
Furthermore, GMS associated with higher T-stage (p<0.001), higher N-stage (p=0.002), 
colonic site (p=0.021) and higher-risk TNM III disease (p<0.001). 
The interaction between GMS and adjuvant chemotherapy type and duration was 
investigated (Table S5). Multivariate Cox PH analysis was performed, demonstrating a 
significant interaction between GMS and chemotherapy type (p=0.01) but not duration 
(p=0.64).   As an interaction was seen between GMS and chemotherapy type, associations 
with DFS where stratified for FOLFOX and CAPOX. For patients receiving FOLFOX, the 
association with DFS was strengthened with a 5-year DFS for GMS 0, 1 and 2 of 88%, 62% 
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and 54%, respectively (GMS 0 v GMS 2: HR 3.50 95% CI 1.88-6.50, p<0.001, Figure 2B). 
However, for patients receiving CAPOX these associations were dampened with a 5-year 
DFS for GMS 0, 1 and 2 of 62%, 63% and 53%, respectively (GMS 0 v GMS 2: HR 1.33 
95% CI 0.98-1.85, p=0.07, Figure 2C). As associations with DFS were strengthened in the 
FOLFOX-treated patients, patients were stratified by GMS category to assess if any group 
responded more favorably to one particular therapy. Patients with GMS 0 significantly 
benefited from FOLFOX over CAPOX, with 5-year DFS of 88% v 62% (HR 2.23 95% CI 
1.19-4.16, p<0.001, Figure 2D). However, no difference in DFS was seen for GMS 1 with 5-
year DFS for FOLFOX and CAPOX of 62% v 63% (HR 1.08 95% CI 0.88-1.33, p=0.21, 
Figure 2E) or GMS 2 with 5-year of 54% v 53%, respectively (HR 0.90 95% CI 0.68-1.19, 
p=0.68, Figure 2F).  To ensure that the interaction between GMS 0 and chemotherapy type 
was not inadvertently due to one group receiving a longer course of chemotherapy than 
another, a further test of association was performed between type and duration of 
chemotherapy in the GMS 0 subgroup. There was no significant association between 
chemotherapy type and duration in this subgroup (p=0.11; Table S6). 
To assess the utility of GMS in lower- and higher-risk TNM III disease, as defined by 
the SCOT trial, TNM III patients were stratified into lower-risk (T1-3/N1) and higher-risk 
(T4 or N2) groups. GMS did not stratify DFS in the lower-risk patients (GMS 0 v GMS 2: 
HR 1.61 95% CI 1.01-2.57, p=0.13, Figure 3A), but significantly stratified higher-risk 
patients (GMS 0 v GMS 2: HR 1.86 95% CI 1.26-2.76, p=0.002, Figure 3B).  Next, 
interactions with type and duration of chemotherapy were assessed (Table S5). GMS did not 
interact with duration in either group.  GMS interacted with type of chemotherapy in lower-
risk patients (p=0.005) but not higher-risk patients (p=0.61). For patients receiving FOLFOX, 
GMS stratified DFS in both the lower-risk (GMS 0 v GMS 2: HR 5.41 95% CI 1.83-15.98, 
p=0.001, Figure 3C) and higher-risk disease (GMS 0 v GMS 2: HR 2.61 95% CI 1.12-6.12, 
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p=0.03, Figure 3D). However, when assessing chemotherapy type within TNM III patients 
with GMS 0, patients benefited from FOLFOX over CAPOX chemotherapy in lower-risk 
(HR 2.94 95% CI 1.02-8.47, p=0.04, Figure 3E), but not higher-risk disease (HR 1.82 95% 




The results presented from both the expanded validation and TransSCOT cohorts 
validate the utility of GMS as an independent prognostic marker in colorectal cancer. This 
represents the largest study to date investigating a combination scoring system of 
peritumoural inflammation and mesenchymal phenotype. Other microenvironment scores 
have been proposed, such as: the Immunoscore10, which uses immunohistochemical staining 
for CD3 and CD8 and a digital pathology software platform to evaluate immune infiltrates; 
colorectal cancer intrinsic subtypes (CRIS), which uses genetic testing of a number of genes 
implicated in colorectal cancer to stratify tumour behaviour/response23; the Phenotypic 
Subtypes, which have already been addressed in this paper, combining KM, TSP and Ki67 
immunohistochemistry; and the image-based consensus molecular subtype, which uses 
artificial intelligence analysis of digital pathology slides24. GMS has advantages over these 
scores in that it does not require the use of additional immunohistochemical staining, genetic 
testing or digital pathology, as it can be performed on the H&E slides that are used in routine 
clinical practice for TNM staging. Furthermore, in the subset of patients with both GMS and 
IHC available, GMS was strongly associated with CD3 and CD8. In addition, there were 
similar univariate RFS for all scores. This again supports the GMS as a clinically applicable 
prognostic score in patients with colorectal cancer. 
In the validation cohort, GMS stratified survival of both low-risk and high-risk 
patients, in terms of stage and Petersen index, with GMS 2 highlighting a group of low-risk 
patients that may benefit from additional adjuvant therapy. GMS 2 may therefore be 
considered for addition to the current list of high-risk pathological features discussed at 
multidisciplinary team meetings to guide ongoing management. GMS 1 defined a group of 
patients with neither high immunity, nor high TSP who have an intermediate outcome that 
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varies with disease stage, with better survival in low-risk disease, but worse survival in high-
risk disease. Whereas, GMS 0 indicated a group of patients that had a good clinical outcome 
regardless of disease stage, in keeping with previous research in high immune tumours25. 
Patients with GMS 2 appear to reflect a particularly poor prognostic group, with a 
clear reduction in not only OS, but also DFS, CSS and RFS. Previous work has proposed that 
such a phenotype, characterised by high stromal infiltration and weak immune response, 
reflects a mesenchymal subtype with poor prognosis and increased risk of recurrence20. In the 
present study, patients with GMS 2 had the highest risk of both local and distant recurrence. 
Kaplan-Meier curves showed an early and sustained drop in survival of patients with GMS 2, 
particularly over the first two years of follow-up, reflecting the time period in which patients 
are most likely to develop recurrent metastatic disease26. In contrast, survival continued to 
decline gradually throughout follow-up in patients with GMS 0 and 1, likely reflecting 
alternative causes of death in these groups. Indeed, whether patients with GMS 2 may benefit 
from enhanced surveillance strategies would be of interest. 
The association of GMS with chemotherapy regimen was explored in the TransSCOT 
cohort.  GMS survival stratification in the TransSCOT cohort was similar to that in the 
validation cohort. GMS 2 patients derived less benefit from adjuvant chemotherapy 
independent of regimen used or risk stratification. GMS 1 patients did not respond better to 
any particular chemotherapy type but had an intermediate survival outcome. However, for 
GMS 0 patients receiving FOLFOX, survival was significantly better than those receiving 
CAPOX, especially in lower-risk TNM III. This did not appear to reflect differences in 
duration of chemotherapy. 
Whilst further validation is required, the results suggest that those with higher 
peritumoural inflammation have different clinical outcomes depending on which form of 5-
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FU-based chemotherapy is administered.  FOLFOX was shown to offer a more favourable 
outcome in the presence of high peritumoural inflammation (GMS 0). However, in the 
absence of such an infiltrate (both GMS 1 and GMS 2), there was no survival difference.   
Previous studies have reported that colorectal cancer patients receiving chemotherapy 
have better outcomes if they have higher tumour-infiltrating lymphocytes25, 27, 28. However, 
there are no previously published studies that have compared the efficacy of FOLFOX vs 
CAPOX depending on peritumoural inflammation. The link between high KM and type of 
chemotherapy was demonstrated by our group when investigating the 1343 TransSCOT 
patients studied for the Phenotypic Subtypes study20. Since the assessment of Ki67 did not 
add to this differentiation, only the GMS was performed on the full TransSCOT cohort. There 
is, therefore, paucity of data as to the mechanism underlying this effect and further 
investigation is required. One hypothesis is that the high levels of immune cells hamper the 
final stage of capecitabine metabolism, inhibiting its cytotoxic effect and therefore 
dampening the effect of CAPOX. However, as previously stated, patients with higher 
peritumoural inflammation have better outcomes on adjuvant chemotherapy and so this 
explanation holds little weight. Alternatively, the administration of intravenous 5-FU in the 
FOLFOX regimen may result in better bioavailability of the active metabolite, fluoro-
deoxyuridine monophosphate, than oral Capecitabine and this effect would be more 
pronounced in the higher immune group. Further still, Folinic Acid (Leucovorin) is 
administered as part of the FOLFOX regimen as it has been found to enhance the anti-tumour 
effects of 5-FU29. Folinic acid is an intravenous folate and is also used to supplement vitamin 
B9, which can protect against bone marrow suppression30 and this may protect FOLFOX 
patients with high peritumoural inflammation against the immunosuppressive side effects of 
chemotherapy. However, there are no studies to date exploring this phenomenon. 
 20 
Pagès et al.31 recently published results comparing the Immunoscore in the French 
cohort of the IDEA study, finding that those with higher anti-tumour immunity might benefit 
from longer course mFOLFOX6. While the results of the TransSCOT cohort validate the use 
of FOLFOX over CAPOX in this patient group, there was no association between duration of 
treatment and GMS status. 
GMS was unable to significantly stratify disease-free survival of patients with rectal 
cancer in either cohort. There were smaller numbers in this subgroup and this may be one 
reason for the lack of stratification. In addition, a proportion of patients may have received 
neoadjuvant radiotherapy, which would impact upon post-operative tumour 
microenvironment assessment. However, RFS and CSS in the validation cohort showed a 
significant difference for disease recurrence and cancer-specific survival in GMS 0 vs GMS 2; 
this requires further study in additional patient cohorts. 
Lack of mutational data represents a limitation of this study. This could be 
strengthened by combining the GMS with mutational analysis and this represents one of the 
future directions of this group. A further limitation of the current study is the lack of overall 
and cancer-specific survival data in the TransSCOT cohort. However, as shown in the 
validation cohort, the curves were very similar for DFS and overall survival and therefore, 
DFS can be considered a reasonable primary endpoint. 
In conclusion, the present study validates the prognostic utility of the Glasgow 
Microenvironment Score. The poor outcome in low-risk disease of GMS 2 indicates that this 
subgroup may not derive benefit from current therapies. However, GMS 2 may be considered 
an additional high-risk feature that warrants consideration for novel therapies. Conversely, 
GMS 0 in high-risk patients highlights a sub-group that may benefit most from current 
therapies. This survival effect was strengthened in patients receiving FOLFOX but dampened 
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in patients receiving CAPOX. Therefore, GMS could be a useful tool to aid both prognostic 
and therapeutic decision making in clinical practice alongside TNM-staging. GMS should be 
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Figure 1. GMS can stratify recurrence and survival according to disease risk in the 
validation cohort. (A-C) Kaplan Meier curve showing associations between GMS and DFS 
in the (A) full cohort (n=862), (B) “low-risk” colorectal cancer (n=499) and (C) “high-risk” 
colorectal cancer (n=363). (D-E) Kaplan Meier curve showing associations between GMS 
and RFS in the (A) full cohort (n=862), (B) “low-risk” colorectal cancer (n=499) and (C) 
“high-risk” colorectal cancer (n=363). 
 
Figure 2. GMS can identify patient response to adjuvant chemotherapy within the 
TransSCOT cohort. (A) Kaplan Meier curve showing associations between GMS and DFS 
in the full cohort (n=2912). (B,C) Kaplan Meier curves showing associations between GMS 
and DFS in patients receiving (B) FOLFOX (n=846) or (C) CAPOX (n=2066) adjuvant 
chemotherapy. (D-F) Kaplan Meier curves showing associations between chemotherapy type 
and DFS in patients with (D) GMS 0 (n=383), (E) GMS 1 (n=1866) or (F) GMS 2 (n=663). 
 
Figure 3. GMS, prognosis and response to adjuvant chemotherapy in low- and high-risk 
stage III patients from the TransSCOT cohort (n=2356). (A,D) Kaplan Meier curves 
showing associations between GMS and DFS in (A) low-risk (n=1284) and (B) high-risk 
stage III patients (n=1072). (B,E) Kaplan Meier curves showing associations between GMS 
and DFS in (B) low-risk (n=374) and (E) high-risk (n=336) stage III patients receiving 
FOLFOX adjuvant chemotherapy. (C,F) Kaplan Meier curves showing associations between 
chemotherapy type and DFS in GMS 0 patients within the (C) low-risk (n=202) and (F) high-
risk (n=102) stage III groups.   
